Seedlabs

Stay-On Tirzepatide GI Tolerance Service

A coaching service that helps diabetes patients manage stomach side effects so they don't stop taking their medication.

A 12-week telehealth coaching and symptom-monitoring service that keeps patients with type 2 diabetes and heart disease on tirzepatide through its GI side effects — with a protocolized fallback switch to dulaglutide — aimed squarely at the drug's 13.2% adverse-event discontinuation rate.

MedicineDiabetes Treatment and Management
Attention Deficit Hyperactivity DisorderMetabolic telehealth and digital chronic-care clinics

Concept

A white-label retention module that telehealth metabolic clinics and health systems bundle with every new tirzepatide prescription for patients with type 2 diabetes and cardiovascular disease. It has four components: (1) a weekly app-based GI symptom check (nausea, vomiting, reflux, appetite) with numeric severity thresholds; (2) titration-pacing and low-fat, small-portion meal guidance timed to each dose escalation; (3) a nurse-line escalation path to antiemetic or dose-hold protocols when symptom scores cross defined lines; and (4) if symptoms persist after two intervention cycles, a structured in-class switch to dulaglutide 1.5 mg rather than abandoning incretin therapy altogether. The single wedge: convert a known tolerability gap into a managed, retained patient.

Why now

The SURPASS-CVOT trial (13,165 patients with type 2 diabetes and established atherosclerotic cardiovascular disease) just settled tirzepatide's cardiovascular safety against an active comparator with proven benefit — MACE hazard ratio 0.92, noninferiority P=0.003 — but it also precisely quantified the tolerability problem: GI adverse events in 42.5% of tirzepatide patients versus 35.9% on dulaglutide, and discontinuation due to adverse events of 13.2% versus 10.1%. With cardiovascular safety no longer in question, tolerability-driven attrition is now the main fixable barrier to long-term therapy, and the trial provides exact benchmarks a retention service can be measured against.

Written by GLM · 9 Oct 2026

AI assessment

Backed by 1 paper96

A highly pragmatic, evidence-backed retention service that targets a specific, quantified attrition rate in a high-value drug market.

Evidence strength
5/5
The idea is directly derived from the SURPASS-CVOT trial's specific discontinuation rate (13.2%) and the comparative tolerability of dulaglutide, making the clinical logic airtight.
Market pull
5/5
Telehealth giants like Ro and Hims & Hers have massive financial incentives to reduce churn in their most profitable GLP-1 patient cohorts.
Novelty & moat
4/5
While patient monitoring exists, a protocolized 'fallback switch' specifically designed to prevent total therapy abandonment is a distinct and defensible clinical wedge.
Feasibility
5/5
The MVP requires only basic digital tracking and a nurse-led protocol, utilizing existing telehealth infrastructure.
Wedge clarity
5/5
The wedge is exceptionally sharp: reducing the 13.2% adverse-event discontinuation rate for a single drug class.
Simplicity / focus
5/5
The product is a single, focused retention module rather than an over-scoped health platform.

Scored by Gemma 4 · 9 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Hims & Hers Healthcompany

    Its GLP-1 metabolic programs live or die on patient persistence; a service that reduces the 13.2% adverse-event discontinuation rate directly protects subscription revenue.

  • Rocompany

    Ro's weight-management telehealth faces the same churn from GI side effects; a structured tolerance program is a retention lever it can deploy immediately.

  • LifeMDcompany

    LifeMD's GLP-1-focused metabolic offering needs differentiation beyond price; a clinically grounded GI-management pathway improves outcomes and persistence.

  • Omada Healthcompany

    Omada already delivers digital coaching alongside GLP-1 therapy and could white-label this module as the behavioral layer that keeps members on treatment.

  • Eli Lilly and Companycompany

    Lilly makes both tirzepatide and dulaglutide; whether a patient is retained on tirzepatide or protocolized onto dulaglutide, Lilly keeps the patient in its portfolio.

Research it builds on

  1. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
    Stephen James Nicholls, Imre J. Pavo, Deepak L. Bhatt et al. · 2025 · 188 citations
    All ideas from this paper →
Leave feedback
feasibility